Simon Brandt
Professor of Drug Chemistry and Forensic Toxicology at Liverpool John Moores University
Data updated
Research Footprint
Simon Brandt appears in 5 tracked papers (2018–2024), most studied alongside MDMA, Psilocybin and LSD, across Equity and Ethics, Medicinal Chemistry & Drug Development and Healthy Volunteers.
Most-cited paper: Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species (265 citations).
Frequent co-authors: Thomas Passie, John McCorvy and Adam Halberstadt.
Background & Research
Simon D. Brandt is a drug chemist and toxicology researcher based at Liverpool John Moores University. His work has focused on novel psychoactive substances, including MDMA-related compounds, psychedelic analogs such as psilocybin derivatives, and the analytical and pharmacological characterization of emerging drugs. He has also co-authored historical work on self-experimentation with psychoactive substances.
Key Impact
He is a key researcher on novel psychoactive substances and psychedelic/entactogenic analogs, spanning human effects, analytical chemistry, and historical scholarship.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Simon Brandt is associated with.
Liverpool John Moores University
Liverpool John Moores University (LJMU) is a public university in Liverpool, England, United Kingdom, offering undergraduate and postgraduate teaching and research across a wide range of disciplines.
View stakeholder →Alexander Shulgin Research Institute
Non-ProfitThe Alexander Shulgin Research Institute (ASRI) was founded in 2021 by Dr. Nicholas Cozzi, Dr. Paul Daley, and the late Ann Shulgin, continuing the legacy of chemist Alexander Shulgin. The institute maintains the Shulgin Vault — a repository of over 500 compounds synthesized by Shulgin and ASRI scientists. Lead candidate ASR-3001 (5-MeO-iPALT) is an orally active, fast-acting tryptamine with a mild internal psychedelic profile and no visual hallucinations, near IND-ready for psychiatric disorders. ASR-2001 is a non-hallucinogenic compound producing mental clarity.
View stakeholder →